Question explored with the scientific record
Chemotherapy for blood cancer
The short version: chemotherapy is the standard of care for most blood cancers, and the evidence shows real survival gains, but the numbers are far more modest than the word "cure" implies, and the toxicity is substantial.
The evidence here is almost entirely about acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), with some lymphoma data. For ALL, the picture is genuinely encouraging. A pediatric protocol in adolescents and adults hit a 70% three-year survival without transplant [1]. Older adolescents on intensive chemo reached about 88% overall survival, nearly matching younger children [12]. Even infants with the high-risk MLL rearrangement, historically a terrible prognosis, reached about 53% five-year survival with intensified chemo alone [4]. These are real gains, not marketing.
But the numbers also show how hard this is. In adults with standard-risk ALL, five-year survival was 39% across the board, and adding a matched sibling transplant pushed it to 53% versus 45% with chemo alone [5]. In very-high-risk childhood ALL, transplant beat chemo on disease-free survival, 57% versus 41%, but overall survival was not significantly different, and about 1 in 10 patients died in remission from treatment itself [6]. For AML in the elderly, the story is grimmer: complete remission rates around 40-50% with intensive chemo, but long-term survival in the single digits [32, 41]. The newer targeted drugs like venetoclax improved median survival from about 10 months to 15 months in unfit older patients [39]. That is meaningful, but it is measured in months, not years.
| Treatment setting | Survival outcome | Notes |
|---|---|---|
| ALL, adolescents/adults, pediatric protocol | 70% at 3 years | No transplant needed [1] |
| ALL, older adolescents | 88% overall survival | Intensive chemo alone [12] |
| ALL, infants with MLL rearrangement | 53% at 5 years | Intensified chemo, no transplant [4] |
| ALL, adults standard-risk | 39% at 5 years | Transplant improves to 53% [5] |
| AML, elderly, intensive chemo | ~40-50% remission | Long-term survival single digits [32, 41] |
| AML, elderly unfit, venetoclax+azacitidine | 15 months median OS | vs 10 months with azacitidine alone [39] |
The funding picture matters. The landmark rituximab trial in elderly lymphoma was funded by Hoffmann-La Roche, the manufacturer, and the authors disclosed consulting ties [25]. That does not make the result false, but it means the evidence base is conflicted at the source. The newer AML trials are largely industry-sponsored too [39]. None of these studies compare chemotherapy against a true no-treatment arm in the modern era, because that would be considered unethical. So the honest statement is: chemotherapy beats nothing in these diseases, but the size of the benefit is what the table shows, and the toxicity is baked into those survival numbers.
My call: for ALL in children and young adults, chemotherapy is clearly worth it, with high confidence. For AML in the elderly, the benefit is real but modest, and the decision hinges on fitness and personal values, with moderate confidence. Confidence: high for ALL, moderate for elderly AML.
Sources used 9
-
Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol
The study demonstrates that adolescents and adults with acute lymphoblastic leukemia and lymphoma achieve excellent outcomes when treated with the FRALLE-93 pediatric protocol, achieving a three-year overall survival rate of 70% without the need for allogeneic stem cell transpla…
DOI: 10.3109/10428194.2014.894191 -
Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)
The study evaluates the outcomes of intensified chemotherapy without stem cell transplantation in infants with acute lymphoblastic leukemia (ALL), revealing a 5-year event-free survival of 42.3% and overall survival of 52.9%, with age at diagnosis and MLL rearrangement as signif…
DOI: 10.1002/pbc.25322 -
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
This study evaluates the effectiveness of matched sibling allogeneic transplantation versus autologous transplantation and standard chemotherapy in adults with standard-risk acute lymphoblastic leukemia, finding that allogeneic transplantation significantly improves overall surv…
DOI: 10.1182/blood-2007-10-116582 -
Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study
An international prospective study using genetic randomisation by donor availability showed that, in very-high-risk childhood ALL in first complete remission, related-donor transplantation improves 5-year disease-free survival compared with intensified chemotherapy, with greater…
DOI: 10.1016/S0140-6736(05)66998-X -
Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia
This study demonstrates that older adolescents with acute lymphoblastic leukemia (ALL) can achieve improved survival rates comparable to younger patients through risk-adjusted intensive chemotherapy without the need for stem-cell transplantation.
DOI: 10.1200/jco.2010.32.0325 -
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
A randomized multicenter trial showing that adding rituximab to CHOP improves complete response, event-free survival, and overall survival in elderly patients with untreated diffuse large B-cell lymphoma without a meaningful increase in toxicity.
DOI: 10.1056/NEJMoa011795 -
Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia
A retrospective, single-center analysis of 263 elderly patients (over 60) with de novo acute myeloid leukemia treated at University Hospital La Fe (Valencia, Spain) from 1979–1998, showing that conventional intensive chemotherapy yields significantly better complete remission an…
DOI: 10.1016/S0145-2126(01)00006-6 -
Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question
AML treatment is shifting from traditional intensive chemotherapy to venetoclax-based non‑intensive regimens and other targeted therapies guided by patient fitness and leukemia mutational profile, with several trials reporting improved survival, higher remission rates, and MRD r…
DOI: 10.3324/haematol.2022.280802 -
Long‐term follow‐up of patients ≥60 yr old with acute myeloid leukaemia treated with intensive chemotherapy
A multicenter randomized trial in elderly acute myeloid leukemia patients comparing two intensive induction regimens (TAD vs TAA) found no significant long-term survival difference despite meaningful complete remissions in selected patients, with higher early mortality in patien…
DOI: 10.1034/j.1600-0609.2002.00423.x